Spire Wealth Management Sells 2,383 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Spire Wealth Management reduced its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 64.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,334 shares of the biotechnology company’s stock after selling 2,383 shares during the period. Spire Wealth Management’s holdings in Axon Enterprise were worth $393,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Blue Trust Inc. boosted its holdings in shares of Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares during the period. ICA Group Wealth Management LLC acquired a new position in Axon Enterprise during the 4th quarter valued at $26,000. Trivant Custom Portfolio Group LLC acquired a new position in Axon Enterprise during the 1st quarter valued at $31,000. First PREMIER Bank acquired a new position in Axon Enterprise during the 1st quarter valued at $33,000. Finally, Blue Bell Private Wealth Management LLC acquired a new position in Axon Enterprise during the 1st quarter valued at $41,000. 79.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Matthew R. Mcbrady sold 2,000 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $364.66, for a total transaction of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Matthew R. Mcbrady sold 2,000 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the sale, the director now directly owns 4,892 shares in the company, valued at approximately $1,783,916.72. The disclosure for this sale can be found here. Insiders sold 152,750 shares of company stock worth $56,105,818 in the last quarter. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Trading Up 0.8 %

Shares of AXON stock opened at $364.97 on Tuesday. The stock has a market cap of $27.58 billion, a price-to-earnings ratio of 106.72, a P/E/G ratio of 9.78 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The firm has a fifty day moving average of $326.57 and a 200-day moving average of $309.02. Axon Enterprise, Inc. has a 52-week low of $189.12 and a 52-week high of $378.89.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm’s revenue for the quarter was up 34.5% on a year-over-year basis. During the same quarter last year, the company posted $0.80 EPS. On average, equities research analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price for the company. Barclays upped their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and set a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. Northland Securities upped their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Finally, Bank of America assumed coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $358.08.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.